FDA approves Regeneron Eylea injection
Eylea is a recombinant fusion protein, that binds VEGF-A and placental growth factor (PlGF) to inhibit the binding and activation of these cognate VEGF receptors. The recommended dose
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
The therapies include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate) and the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate and glycopyrronium bromide). NVA237and